JP2005507944A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507944A5
JP2005507944A5 JP2003541742A JP2003541742A JP2005507944A5 JP 2005507944 A5 JP2005507944 A5 JP 2005507944A5 JP 2003541742 A JP2003541742 A JP 2003541742A JP 2003541742 A JP2003541742 A JP 2003541742A JP 2005507944 A5 JP2005507944 A5 JP 2005507944A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rna
ribonucleoside
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003541742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507944A (ja
Filing date
Publication date
Priority claimed from GB0126701A external-priority patent/GB0126701D0/en
Priority claimed from US10/207,005 external-priority patent/US7049303B2/en
Application filed filed Critical
Publication of JP2005507944A publication Critical patent/JP2005507944A/ja
Publication of JP2005507944A5 publication Critical patent/JP2005507944A5/ja
Withdrawn legal-status Critical Current

Links

JP2003541742A 2001-11-07 2002-11-07 ウイルスの抑制における改善およびその関連 Withdrawn JP2005507944A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0126701A GB0126701D0 (en) 2001-11-07 2001-11-07 Improvements in or relating to induction of mutations in viruses
US10/207,005 US7049303B2 (en) 2001-11-07 2002-07-30 Inhibition of viruses
PCT/GB2002/005031 WO2003039450A2 (en) 2001-11-07 2002-11-07 Improvements in or relating to inhibition of viruses

Publications (2)

Publication Number Publication Date
JP2005507944A JP2005507944A (ja) 2005-03-24
JP2005507944A5 true JP2005507944A5 (cg-RX-API-DMAC10.html) 2006-01-12

Family

ID=26246745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541742A Withdrawn JP2005507944A (ja) 2001-11-07 2002-11-07 ウイルスの抑制における改善およびその関連

Country Status (5)

Country Link
US (2) US7049303B2 (cg-RX-API-DMAC10.html)
EP (1) EP1441744A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005507944A (cg-RX-API-DMAC10.html)
AU (1) AU2002337388A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003039450A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418498A (en) * 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
US7169918B2 (en) * 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
AU2006222563A1 (en) * 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP3042660A3 (en) * 2008-04-15 2016-10-26 RFS Pharma, LLC. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
JP5719840B2 (ja) * 2009-06-08 2015-05-20 武田薬品工業株式会社 Ｊａｋの阻害剤としてのジヒドロピロロナフチリジノン化合物
US9809616B2 (en) 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
WO2023152709A1 (en) * 2022-02-14 2023-08-17 Arbutus Biopharma Corporation Rna polymerase inhibitors and methods using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
WO1990006319A1 (en) 1988-12-05 1990-06-14 Schering Corporation Antiviral dimers and trimers
DK62592D0 (cg-RX-API-DMAC10.html) * 1992-05-14 1992-05-14 Novo Nordisk As
US5773424A (en) 1994-12-16 1998-06-30 Research Corporation Technologies, Inc. Treatment of toxoplasmosis
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
AU727177B2 (en) 1996-10-16 2000-12-07 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
NZ507848A (en) * 1996-10-28 2005-01-28 Univ Washington Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2003524636A (ja) 1999-12-22 2003-08-19 インスパイアー ファーマシューティカルズ，インコーポレイティド プリン性受容体アゴニストによる胃腸管の処置方法

Similar Documents

Publication Publication Date Title
EP0610444B1 (en) Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases
RU2011139180A (ru) Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции
CA2632626A1 (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
WO2011088561A1 (en) Anti-viral compounds and compositions
JP2022537047A5 (cg-RX-API-DMAC10.html)
GB2613516A (en) Formulations of anti-viral compounds
KR20050044587A (ko) Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
JP2025508656A5 (cg-RX-API-DMAC10.html)
JPWO2023054732A5 (cg-RX-API-DMAC10.html)
CA2373833A1 (en) Medicinal compositions for preventing or treating viral myocarditis
JP2022531251A5 (cg-RX-API-DMAC10.html)
KR940010441B1 (ko) B형감염의 항비루스제
US5039667A (en) Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
JP2024544532A5 (cg-RX-API-DMAC10.html)
CN1943782A (zh) 治疗禽流感感染
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
JP2023502053A5 (cg-RX-API-DMAC10.html)
JP2002533470A5 (cg-RX-API-DMAC10.html)
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
EP0137807A1 (en) Antiviral composition and method for administering the same
EP3600332B1 (en) Hiv post-exposure prophylaxis
WO2022200615A1 (en) Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
HK1048951A1 (zh) 与PEG-IFN-α结合的霉酚酸酯MOFETIL
JP2004155777A (ja) Ｃ型慢性肝炎治療剤
AU2020318808A1 (en) HIV pre-exposure prophylaxis